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Nuclear factor (NF)-kB/p65 regulates the transcription of a wide variety of genes involved in cell survival, invasion and metastasis. We
characterised by immunohistochemistry the expression of NF-kB/p65 protein in six histologically normal prostate, 13 high-grade
prostatic intraepithelial neoplasia (PIN) and 86 prostate adenocarcinoma specimens. Nuclear localisation of p65 was used as a
measure of NF-kB active state. Nuclear localisation of NF-kB was only seen in scattered basal cells in normal prostate glands.
Prostatic intraepithelial neoplasias exhibited diffuse and strong cytoplasmic staining but no nuclear staining. In prostate
adenocarcinomas, cytoplasmic NF-kB was detected in 57 (66.3%) specimens, and nuclear NF-kB (activated) in 47 (54.7%).
Nuclear and cytoplasmic NF-kB staining was not correlated (P¼0.19). By univariate analysis, nuclear localisation of NF-kB was
associated with biochemical relapse (P¼0.0009; log-rank test) while cytoplasmic expression did not. On multivariate analysis, serum
preoperative prostate specific antigen (P¼0.02), Gleason score (P¼0.03) and nuclear NF-kB( P¼0.002) were independent
predictors of biochemical relapse. These results provide novel evidence for NF-kB/p65 nuclear translocation in the transition from
PIN to prostate cancer. Our findings also indicate that nuclear localisation of NF-kB is an independent prognostic factor of
biochemical relapse in prostate cancer.
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Nuclear factor (NF)-kB/Rel transcription factors represent a group
of structurally related proteins, with five members in mammals,
including p65 (also known as RelA) (Baldwin, 1996; Ghosh et al,
1998; Karin et al, 2004). Nuclear factor-kB is rendered inactive in
nonstimulated cells in the cytoplasm due to its association to NF-
kB inhibitory proteins, known as IkBs. The activation of NF-kB,
and in particular of p65, results from the polyubiquitinination and
subsequent 26S proteasome degradation of IkBs, which allows then
the translocation of p65 to the nucleus. Nuclear p65 initiates the
transcription of a wide variety of genes that code for angiogenic
factors, cell adhesion molecules, antiapoptotic factors and
cytokines, which are involved in cell survival, tumour invasion
and metastasis. Extensive studies performed on cancer cell lines
and preclinical models support a role of NF-kB in cancer
development and progression (Karin et al, 2002). Recently, a
number of studies in human solid tumours and haematological
malignancies have also provided clinical data to support the
concept that NF-kB may have an important role in vivo in human
cancer (Rayet and Gelinas, 1999; Karin et al, 2002). The
importance of further characterisation of NF-kB expression in
clinical cancer specimens is highlighted by the current efforts to
develop novel drugs that inhibit NF-kB activation with the ultimate
goal to use them for cancer treatment (Orlowski and Baldwin,
2002; Karin et al, 2004).
Prostate cancer is the second leading cause of death in men from
cancer. Despite the availability of local treatment with radical
prostatectomy or radiotherapy, which are often curative, many
patients develop disease relapse after primary therapy. The first
sign of prostate cancer recurrence is often heralded by an increase
of serum prostate-specific antigen (PSA) levels and is known as
biochemical relapse. Subsequently, patients can develop clinical
relapse of the disease typically featuring bone metastases (Pound
et al, 1999). It is widely held that the discovery of novel biomarkers
designed to predict the risk of relapse or that could be used as
targets of new targeted anticancer agents are clearly needed (Ross
et al, 2003). Along this line, several preclinical observations have
shown that NF-kB plays a role in prostate cancer growth, survival,
angiogenesis and metastatic progression (Muenchen et al, 2000; Yu
et al, 2000; Catz and Johnson, 2001; Huang et al, 2001; Gasparian
et al, 2002; Gunawardena et al, 2002; Gupta et al, 2002; Suh et al,
2002; Zerbini et al, 2003; Suh and Rabson, 2004). Furthermore,
emerging data obtained from human studies also suggest a
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its behaviour in a clinical setting (Suh et al, 2002; Lessard et al,
2003; Fradet et al, 2004; Ismail et al, 2004; Ross et al, 2004). In
particular, a recent study showed that total overexpression of p65,
the best characterised NF-kB protein, was an independent
predictor of poor prognosis in prostate cancer patients (Ross
et al, 2004). Of note in this study was the fact that nuclear NF-kB
expression was not specifically linked with disease relapse.
However, in another study performed in patients with prostate
cancer and pathologically positive surgical margins in the
prostatectomy specimens, NF-kB nuclear localisation was asso-
ciated to a high risk of biochemical relapse (Fradet et al, 2004).
In the present study, we characterised by immunohistochem-
istry (IHC) the expression and subcellular localisation patterns of
NF-kB in normal prostate, prostatic intraepithelial neoplasia (PIN)
and prostate adenocarcinoma (PAC). The results revealed that NF-
kB/p65 nuclear translocation occurs in the transition of PIN to
prostate cancer. We also assessed whether nuclear NF-kB
expression (used as a measure of the active state of NF-kB), when
separately analysed, predicts biochemical relapse in 86 PAC
patients. The results of this series, the largest reported to date,
confirm a link between NF-kB and prostate cancer outcome and
extend prior reports by showing that nuclear NF-kB (the
biologically active form) is the strongest independent prognostic
factor of biochemical relapse in men that underwent prostatect-
omy as assessed by a comprehensive multivariate analysis. A
combined prognostic analysis taking into account preoperative
PSA levels, Gleason grade and nuclear localisation of NF-kB
staining identified subsets of patients with markedly different risks
of biochemical relapse.
MATERIAL AND METHODS
Specimen collection and patients
A total of 105 tissue specimens were selected for the present study
following institutional guidelines. Paraffin blocks containing
sufficient formalin-fixed tissue for marker analyses were obtained
from six histologically normal prostate specimens, 13 cases of high
grade PIN, and 86 PACs. The selected tissues were obtained from
86 radical prostatectomy specimens that were performed for
biopsy-proven PAC at the Hospital Clinic of Barcelona. The
normal prostatic tissues and high-grade PIN lesions came from the
same patients with from whom prostate cancer was assessed. All
clinical follow-up studies were also performed at the Hospital
Clinic. This study was part of a project funded by the Spanish
Science and Technology Ministry (MCYT; Grant Number SAF
2003–08181) that had been approved by the Ethics Committee of
our institution.
Clinico-pathological data of prostate cancer patients
Tumour Gleason grading (Gleason, 1992), preoperative PSA serum
levels, surgical margins, lymph-node status, seminal vesicle
invasion, and pathological staging (Ohori et al, 1994) were
collected from the 86 prostate cancer patients. Gleason scores
were classified as high grade when the combined Gleason score
was X7 and low grade when the combined Gleason score was p6
(Ross et al, 2004). Serum PSA was measured with Access Hybritech
PSA assay (Beckman, San Diego, CA, USA). Serum PSA levels were
obtained from patients prior to prostatectomy and classified as low
when PSA levels were o10ngml
 1 and high when PSA levels were
X10ngml
 1 (Ross et al, 2004). An elevation of PSA from the
baseline level post-prostatectomy to 40.4ngml
 1 on two con-
secutive occasions was considered to be biochemical evidence of
disease relapse. Surgical margins were defined as positive or
negative. Pathologic stage was T2a, 14 (16.3%) patients; T2b, 37
(43.0%) patients, T3a, 22 (25.6%) patients; and T3b, 13 (15.1%)
patients. Pathologic stage was classified as organ-confined (stage
T2a and T2b) and advanced tumour (stage T3a and T3b) (Ross
et al, 2004). Seminal invasion was classified absent in 73 (84.8%)
tumours and present in 13 (15.2%). Lymph-node status was
negative for metastatic disease in 81 (91.1%) patients and positive
in 5 (5.9%). Follow-up data was obtained from review of the
patients’ medical records.
Tissue microarray
Tissue microarrays were constructed following standard metho-
dology. After selection of donor areas by microscopic examination,
2mm punches were placed in a receptor block measuring
27 30mm. Each microarray block contained a maximum of 80
punches and duplicates of each tumour were produced. Prior to
sectioning, the surface of each microarray block was briefly heated
on a hot plate to improve adhesion of the cores within the block.
Each block was serially sectioned at 2–4mm using a Microm
HM330 microtome. The sections were floated out on a water bath
at 451C and picked up onto sequentially numbered slides (DAKO).
The slides were dried at 371C overnight prior to staining. Standard
sections were also taken from original tumour blocks in selected
specimens to compare the immunohistochemical findings of the
microarray sections with those of standard (larger) sections.
Immunohistochemistry
Briefly, 2–4mm formalin-fixed paraffin-embedded sections from
tissue microarray blocks were deparaffinised and rehydrated.
Antigen retrieval was performed by heating slides in a pressure
cooker in citrate buffer pH 6 for 5min. The primary antibody, an
IgG1 class rabbit polyclonal antibody against the carboxy terminus
of p65/RelA component of the NF-kB complex (sc-372, C-20, Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) was used at a
dilution of 1:180. The slides were incubated with the primary
antibody for 60min, washed in ChemMate buffer solution (DAKO)
and developed using the Envision signal detection system and the
Techmate 500 equipment (DAKO Corp., Glosstrup, DM). To
confirm the specificity of the primary antibody, immunoreactivity
was blocked by preabsortion of the primary antibody with an
excess amount of p65 antigen peptide (sc-372P, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA).
Immunoreactivity for NF-kB was evaluated in normal prostate,
PIN and PAC. Nuclear factor-kB staining was semiquantitatively
assessed as þ (low staining), þþ (moderate staining) and
þþþ(strong staining), essentially following criteria previously
reported by one of us (JSR). After initial assessments, PIN lesions
had strong staining for p65 and cells of normal glands a weak
staining. This information was used as the basis for further
scorings. Specimens with þþþ scoring had an intensity of
staining similar to that observed in PIN lesions and specimens
with þ scoring had an intensity of staining similar to that
observed in histologically normal prostatic epithelial cells. The
þþ scoring was used for tumour cells, which expressed an
intermediate degree of intensity. The percentage of cytoplasmic
and nuclear staining was obtained from the average of the positive
staining cells obtained in duplicate cores.
Staining of NF-kB in surrounding inflammatory cells and
endothelial cells served as internal positive control signals. At least
two investigators, blinded to clinical data, scored each sample.
Concordance between investigators for nuclear NF-kBs t a i n i n gw a s
495%. A third investigator reviewed discordant cases.
Immunofluorescence assay
The ability of the anti-p65 antibody used in IHC assays (sc-372,
C-20; Santa Cruz) to detect nuclear translocation/activation of
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We performed the immunofluorescence experiment as a part of the
validation process of the anti-p65 antibody to be used in IHC. The
human prostate cancer cell line (PC-3) was grown in F-12K
Nutrient Mixture (Gibco, California) medium supplemented with
10% foetal bovine serum. Cells were seeded in 35-mm tissue
culture plates on sterile glass coverslips at a cell density of 200000
cells per plate. Cells were treated with tumour necrosis factor
(TNF)-a 100ngml
 1 (CalBiochem, California) during 10min. Cells
were then fixed with methanol and washed with PBS. After
blocking with PBS plus BSA 1%, cells were incubated with
the primary anti-p65 antibody at a dilution of 1:180 during 2h
at 371C. Then cells were washed with PBS and incubated with
the secondary antibody Alexa Fluor 594-coupled goat-antirabbit
IgG at a dilution of 1:1000 during 1h at 371C. The slides were
further washed with PBS and then mounted with Mowiol
(CalBiochem) for fluorescent microscopic examination. Fluores-
cence confocal and phase images were acquired using a Leica
TCS SL laser scanning confocal spectral microscope (Leica
Microsystems, Heidelberg GmbH, Manheim, Germany). Image
assembly and treatment were performed using the Image
Processing Leica Confocal Software.
Statistical analysis
Statistical analysis was carried out with SPSS version 11.0 (SPSS,
Inc., Chicago, IL, USA). To analyse correlations between p65
expression and other clinico-pathological variables, we used
Spearman’s correlation tests when the two variables were assessed
as continuous, t-test when one variable was assessed as continuous
and the other as qualitative and w
2 test (Fisher exact test) when the
two variables were qualitative. Biochemical disease recurrence was
analysed by the Kaplan–Meier method. Curves were compared by
the log-rank test. Multivariate analysis including continuous
quantitative and qualitative clinicopathological parameters was
performed using the Cox proportional hazards model. All the
statistical tests were conducted at the two-sided 0.05 level of
significance.
RESULTS
Immunohistochemical expression of NF-jBi n
histologically normal prostate, prostate intraepithelial
neoplasia and prostate cancer tissues
To confirm the specificity of the anti-p65 antibody (C-20, Santa
Cruz) used in this study, immunoreactivity was blocked by
preabsortion with a specific antigen peptide. This resulted in
abrogation of tissue staining (Figure 1A and B). In addition, to
assess the ability of the antibody to detect p65 nuclear transloca-
tion, we performed an immunofluorescence assay in cultured cells
under controlled conditions (Figure 1C and D). Human PC-3
prostate cancer cells were treated with TNF-a, a classical activator
of p65/NF-kB. In the absence of TNF-a, cells exhibited prominent
cytoplasmic staining of NF-kB while nuclear staining was not
detected. Following a short course of TNF-a, the nuclei of tumour
cells became intensely stained with the anti-p65 antibody
indicating the translocation of NF-kB from the cytoplasm to the
nucleus. Finally, Western blot experiments performed as pre-
viously reported (Albanell et al, 2001) confirmed that the antibody
detected a band of approximately 65kDa, which corresponds to
the molecular weight of p65 (data not shown).
Staining patterns (i.e. nuclear and/or cytoplasmic p65) between
duplicate cores were concordant in all the specimens (n¼102) for
which duplicates were assessable. Only in three cases (2.9%), one
of the cores was not available for analysis. To further validate the
data obtained in the tissue microarray, we compared the IHC
results of NF-kB/p65 protein staining on whole tissue sections of
14 specimens with the results observed on core biopsies
represented in the microarray. All 14 specimens showed the same
NF-kB cytoplasmic and nuclear expression patterns, whether
assayed in the microarray cores or in the whole tissue sections
(data not shown), thus supporting the data generated in the
microarray.
Normal prostate luminal epithelial cells typically showed
NF-kB staining restricted to the cytoplasm (Figure 2A). This
cytoplasmic staining was of weak to moderate intensity. In
contrast, nuclear NF-kB staining was identified in scattered basal
cells of normal glands and was undetected in luminal cells. We also
analysed NF-kB expression in high-grade PIN lesions, which are
considered as precursors of prostate cancer (Ashida et al, 2004;
Bostwick and Qian, 2004). The 13 PIN specimens showed
cytoplasmic immunoreactivity of strong intensity in the vast
majority of epithelial cells. No nuclear immunoreactivity was
observed in PIN lesion (Figure 2B). The cytoplasmic staining of
cells in PIN was of stronger intensity than that of histologically
normal prostatic epithelial cells. The high epithelial density that
characterises PIN lesions sometimes resulted in an overlap of
cytoplasmic NF-kB staining that may be misinterpreted as
some degree of nuclear staining (ie apical snout). However, on
careful pathological review, nuclear staining in PIN lesions was
undetected.
We also analysed 86 PACs from patients whose clinico-
pathological data and follow-up were available (Table 1). Prostate
cancer tissues showed variable patterns of NF-kB cytoplasmic and
nuclear immunostaining (Figure 2C and D). Cytoplasmic im-
munoreactivity for NF-kB was negative (ie undetected) in 29
(33.7%) PAC specimens and positive in 57 (66.3%). The scored
Table 1 Clinicopathological characteristics of the patients with prostate
adenocarcinomas (n¼86)
Mean age 66 years (range, 45–79 years)
Mean follow-up time 57 months (range, 12.6–100 months)
Mean PSA level 10.92ngml
 1 (range, 0.61–34ngml
 1)
PSA
o10ngml
 1 51 patients (59.3%)
X10ngml
 1 35 patients (40.7%)
Gleason grade
p6 35 patients (40.7%)
X7 51 patients (59.3%)
Stage
Organ confined (T2a,T2b) 51 patients (59.3%)
T2a 14 patients (16.3%)
T2b 37 patients (43.0%)
Advanced (T3a,T3b) 35 patients (40.7%)
T3a 22 patients (25.6%)
T3b 13 patients (15.1%)
Surgical margins
Negative 54 patients (62.7%)
Positive 32 patients (37.3%)
Seminal vesicle invasion
Absent 73 patients (84.8%)
Present 13 patients (15.2%)
Lymph node status
Negative 81 patients (94.1%)
Positive 5 patients (5.9%)
Biochemical relapse 33 patients (38.3%)
Metastasis 6 patients (6.9%)
Prostate cancer related deaths 3 patients (3.5%)
NF-jB in human prostate cancer
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sFigure 1 Upper panels. Immnunohistochemical stain for p65 in prostate cancer tissues. (A) Prostate cancer staining with the antibody to NF-kB/p65 (C-
20, sc-372, Santa Cruz) dilution 1:180, magnification  400. (B) Immunoreactivity was blocked by preabsortion of the primary antibody with the antigen
peptide (sc-372 P, Santa Cruz), magnification  400. Lower panels. Immunofluorescence stain for p65 prostate cancer cells (PC-3). (C) Inmunofluorescence
staining with the antibody to NF-kB p65 (C-20, Santa Cruz, dilution 1:180) in nonstimulated human prostate cancer cells (PC-3) shows only cytoplasmic
staining. (D) PC-3 cells stimulated with TNF-a 100ngml
 1 for 10min exhibit nuclear staining.
Figure 2 Patterns of NF-kB immunoreactivity in prostate tissues (diaminobenzidine with hematoxylin counterstaining; magnification,  400). (A) Cells of
normal prostate glands with weak cytoplasmic NF-kB staining while nuclear NF-kB staining was only seen in scattered basal cells (arrows). (B) High-grade
prostate intraepithelial neoplasia with intense cytoplasmic NF-kB staining. No nuclear immunoreactivity was seen in cells of PIN lesions. (C) Prostate cancer
specimen with diffuse cytoplasmic NF-kB staining but no nuclear immunoreactivity. (D) Prostate cancer specimen with both cytoplasmic and nuclear NF-kB
staining in tumour cells.
NF-jB in human prostate cancer
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specimens, þþin 32 (37.2%) and þþþin 3 (3.4%). Nuclear
factor-kB nuclear staining was negative in 39 (45.3%) specimens
and positive in 47 (54.7%). The scored intensities of nuclear
immunoreactivity was þ in 22 (25.6%) specimens, þþ in 15
(17.4%) and þþþ in 10 (11.6%). No correlation between
cytoplasmic and nuclear NF-kB staining was observed (w
2 test
P¼0.19). In total, 16 (18.6%) PACs were negative for both nuclear
and cytoplasmic NF-kB, 23 (26. 8%) were nuclear negative/
cytoplasmic positive, 13 (15.1%) were nuclear positive/cytoplasmic
negative and 34 (39.5%) were both nuclear and cytoplasmic
positive. Several PAC specimens were scored as negative for both
nuclear and cytoplasmic NF-kB. Although these specimens might
lack the p65 subunit of NF-kB, it is also possible that under the
immunohistochemical assay conditions used, the level of expres-
sion was below the limits of detection. No significant correlations
were observed between nuclear or cytoplasmic staining for NF-kB
and pathologic stage of the disease, Gleason score, preoperative
serum PSA levels, surgical margins and seminal vesicle invasion.
In more detail, no statistically significant correlations were
observed between the percentage of cells with nuclear NF-kB
staining and the following factors: Gleason score (Spearman,
P¼0.79), PSA (Spearman, P¼0.34), stage (Spearman, P¼0.29),
seminal vesicle invasion (t-test, P¼0.10), lymph node status
(t-test, P¼0.86) or surgical margins (t-test, P¼0.26). Similarly,
the percentage of cells with cytoplasmic NF-kB staining did
not statistically correlate with Gleason (Spearman, P¼0.07),
PSA (Spearman, P¼0.46), stage (Spearman, P¼0.18), seminal
vesicle invasion (t-test, P¼0.25), lymph node status (t-test,
P¼0.87) or surgical margins (t-test, P¼0.58). Furthermore,
correlation tests performed analysing the clinico-pathologic
parameters as binarised continuous variables also lacked
statistically significance (Table 2). Since specimens of normal
prostate or high-grade PIN lesions were from patients that also
had prostate cancer, we assessed whether there was any particular
pattern of nuclear NF-kB staining in the corresponding
tumours. Tumour cells showed nuclear NF-kB staining in three
out of the six patients for whom normal prostate was also assessed
and in eight out of the 13 patients for whom high-grade PIN
lesions were also assessed. These observations suggest that nuclear
translocation of NF-kB occurs during the malignant transforma-
tion of the prostate.
NF-jB cytoplasmic and nuclear expression and disease
recurrence
The relationship between NF-kB expression and the risk of
biochemical relapse was assessed using Kaplan–Meier disease
outcome analysis. Using a bimodal approach, the presence or
absence of NF-kB cytoplasmic staining was not associated with the
risk of biochemical relapse of the disease (Figure 3A; log-rank test,
P¼0.74). Using a semiquantitative scoring assessment approach
(0, þ, þþ, þþþ), cytoplasmic NF-kB expression was
similarly not significantly associated with the risk of biochemical
relapse (data not shown).
In contrast, NF-kB nuclear staining was a prognostic factor for
biochemical relapse of the disease (Figure 3B). Patients with
positive nuclear NF-kB expression had a median time to
biochemical relapse of the disease of 44 months, while tumours
lacking NF-kB nuclear staining did not reach median time to
biochemical relapse. The actuarial 5-year biochemical relapse-free
survival was 34% in patients with positive nuclear NF-kB staining
and 78% patients with negative nuclear NF-kB (Figure 3B; log-rank
test, P¼0.0009). Using a semiquantitative scoring assessments
(0, þ, þþ, þþþ) approach did not further improve the
prognostic value of nuclear NF-kB (data not shown). Kaplan–
Meier survival curves for biochemical relapse and log-rank test
comparisons also showed that high PSA preoperative levels
(P¼0.0001), high Gleason score (P¼0.0056) and positive surgical
margins (P¼0.02) were also associated with a higher risk of
relapse in log-rank test analysis. Patients with advanced stage
also had a worse prognosis than patients with early stage
disease, although the differences were not statistically different
(P¼0.23).
On multivariate analysis, positive nuclear NF-kB staining
(P¼0.002), Gleason score (P¼0.03) and preoperative PSA serum
levels (P¼0.02) were independent prognostic factors for bio-
chemical relapse when all the analysed variables were assessed as
binarised variables (Table 3). A second multivariate analysis was
performed using nuclear NF-kB, cytoplasmic NF-kB, PSA serum
levels, Gleason score and Stage as continuous variables, and
surgical margins, seminal vesicle invasion and lymph node status
as qualitative variables. In this multivariate analysis, NF-kB
nuclear staining (P¼0.003) and Gleason score (P¼0.008) were
the variables found as independent prognostic factors for
biochemical relapse (Table 3). Since nuclear NF-kB was an
independent factor, we then analysed the recurrence curves for
patients with positive NF-kB nuclear staining stratified by the
presence or absence of high Gleason score and/or high preopera-
tive PSA. Notably, all tumours featuring the presence of all three
adverse prognostic factors experienced biochemical relapse of the
disease. Tumours with nuclear NF-kB expression and no
additional risk factors (ie low Gleason and low preoperative
PSA) had the lowest rate of biochemical recurrence in the nuclear
NF-kB positive group. Tumours with positive NF-kB nuclear
staining and only one of the two additional adverse prognostic
factors (ie high Gleason or high preoperative PSA, but not both)
had an intermediate rate of biochemical disease relapse (Figure 3C;
log-rank test, P¼0.0032). Finally, the incidence of biochemical
disease recurrence in tumours with no nuclear NF-kB staining
varied according to the presence or absence of high preoperative
PSA or high tumour grade. In tumours that were devoid of nuclear
NF-kB expression and were also low grade and featured a low
preoperative serum PSA level, 0 (0%) experienced biochemical
relapse during the available follow-up period (Figure 3D; log-rank
test, P¼0.046).
Table 2 Nuclear and cytoplasmic immunoreactivity to NF-kB in PACs specimens and clinicopathological characteristics (n¼86)
Nuclear Cytoplasmic
NF-jB+(n¼47) NF-jB (n¼39) P NF-jB+(n¼57) NF-jB (n¼29) P
High grade
a (n¼51) 23/47 (48.9%) 28/39 (73.7%) 0.56 35/57 (61.4%) 16/29 (55.2%) 0.56
Advanced Stage
a (n¼35) 19/47 (40.4%) 16/39 (41.0%) 0.30 22/57 (38.6%) 13/29 (44.8%) 0.57
Positive margin
a (n¼32) 12/47 (25.5%) 20/39 (51.3%) 0.14 23/57 (40.3%) 9/29 (31.0%) 0.39
Mean7s.d. PSA
b 9.7776.25 11.7877.64 0.29 10.6576.35 11.4578.47 0.62
Presence of seminal vesicle invasion (n¼13) 6/47 (12.7%) 7/39 (17.9%) 0.50 5/57 (8.7%) 8/29 (27.8%) 0.61
Positive lymph-nodes
c (n¼5) 5/47 (10.6%) 0/39 (0%) 0.06 2/57 (3.5%) 3/29 (10.3%) 0.20
aw
2 test.
bStudent’s t test.
cFisher’s exact test. For Spearman’s correlation tests, see text.
NF-jB in human prostate cancer
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In the present study, we provide novel data that strongly point to
NF-kB nuclear translocation (ie activation) as a late event in
prostate cancer development and also that nuclear NF-kB
expression is an independent predictor of a significantly increased
risk of biochemical (PSA) relapse in patients that underwent
prostatectomy. Furthermore, a combined prognostic analysis
taking into account preoperative PSA levels, Gleason grade and
nuclear NF-kB staining could identify subsets of patients with
markedly different risks of biochemical relapse.
In histologically normal prostatic glands, NF-kB expression was
generally weak and located in the cytoplasm of the luminal
epithelial cells whereas nuclear staining was only seen in scattered
basal cells. In PIN lesions, NF-kB was exclusively overexpressed in
the cytoplasm and nuclear NF-kB was not detected. For PAC, NF-
kB expression and its subcellular localisation were highly variable
among different specimens. There was no correlation between NF-
kB nuclear and cytoplasmic staining. Since PAC, PIN and
histologically normal specimens came from the same patients
and staining patterns differed, this evokes an apparent lack of any
detectable paracrine mechanism of NF-kB activation.
The molecular determinants of the diverse patterns in NF-kB
expression and subcellular localisation in prostate cancer deserve
further studies. The current observations suggest that in the early
stages of prostate tumorigenesis (i.e. in PIN lesions) (Sasaki et al,
2001; Yu et al, 2003), cytoplasmic NF-kB levels increase by as yet
unknown mechanisms and nuclear translocation of NF-kB does
not occur until invasive cancer develops. Along this line, it has
been shown recently that the majority of prostate cancer lymph
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NF-B +; Gleason 7 and
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Figure 3 Upper panels, Kaplan–Meier survival curves for cytoplasmic and nuclear NF-kB expression in prostate adenocarcinomas. (A) No association
between NF-kB cytoplasmic expression and biochemical disease recurrence was detected (P¼0.74). (B) Nuclear expression of NF-kB was associated to
the chance of biochemical disease-free survival. Patients with nuclear NF-kB had a higher risk of biochemical disease recurrence compared with those whose
primary tumours did not have nuclear NF-kB( P¼0.0009). Lower panels, Kaplan–Meier survival curves for NF-kB nuclear expression combined with
presurgical serum prostate specific antigen (PSA) levels and Gleason score. (C) Patients with positive nuclear NF-kB expression and both (PSAX10ngml
 1
and gleason X7) adverse prognostic factors had a greater chance of biochemical disease recurrence than those who presented one (PSAX10ngml
 1 or
gleason X7) or no (PSAp10ngml
 1 and gleasonp6) adverse independent prognostic factors (P¼0.0032). (D) Patients with negative nuclear NF-kB
expression, PSAo10ngml
 1 and Gleasonp6 presented had a better prognosis compared to patients with negative nuclear NF-kB expression and one
(PSAX10ngml
 1 or gleasonX7) or both (PSAX10ngml
 1 and gleasonX7) adverse independent prognostic factors (P¼0.046).
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snode metastasis had evident nuclear NF-kB staining (Ismail et al,
2004). These findings in prostate tumorigenesis are consistent with
previous observations in other cancer types, such as gastric (Sasaki
et al, 2001), uterine cervix (Nair et al, 2003), colorectal (Yu et al,
2003), breast (Biswas et al, 2004), and head and neck squamous
cell cancers (Nakayama et al, 2001), showing that NF-kB activation
occurs mainly in established cancer tissues rather than in normal
or premalignant lesions.
In the present study, NF-kB staining was not significantly
linked to other known prognostic factors of biochemical relapse
such as preoperative PSA levels, surgical margins or Gleason
grade. Others have reported similar findings, thus suggesting that
NF-kB expression may add to current established prognostic
factors in prostate cancer (Ismail et al, 2004). Along this line, in the
present series, immunohistochemical nuclear NF-kB staining/
activation in prostate cancer was an independent prognostic
factor of biochemical relapse for prostate cancer patients. We
found statistically significant differences in biochemical free-
survival as a function of NF-kB expression, suggesting the
potential biological relevance of this marker. PSA relapse occurred
typically months or years after prostatectomy and, therefore, the
possibility of NF-kB nuclear activation and PSA increase favored
by inflammatory stimulus in the prostate gland, can be excluded.
Although the shortest follow-up was of 12.6 months (a single
patient), the mean follow-up of the series was 57 months and
allowed to have a number of relapses high enough to detect
outcome differences. Patients with nuclear NF-kB staining had a
hazard ratio for biochemical relapse five-fold higher than patients
with no NF-kB nuclear staining. This prognostic significance of
NF-kB in PACs reveals that the biologically active/nuclear form of
NF-kB is linked to outcome.
A prior study showed that total overexpression of NF-kBb y
IHC on prostatectomy specimens was as an independent
prognostic factor in human prostate cancer (Ross et al, 2004).
Since it is extensively considered that cytoplasmic NF-kBi s
an inactive form with nuclear translocation required for activation,
nuclear staining was also specifically analysed in that study.
However, NF-kB nuclear localisation was unrelated to the risk
of biochemical relapse (Ross et al, 2004). Notably, the rate of
nuclear NF-kB staining (15%) in the study by Ross et al was
lower than what we report in the present study (54.7%) or other
reports (Fradet et al, 2004). We showed that the antibody
used in the present work detected nuclear translocation (activa-
tion) of NF-kB/p65 under controlled experimental cell culture
conditions. In prostate cancer cells stimulated with TNF-a, the
antibody exhibited strong nuclear staining, as assayed by
immunofluorescence, while in nonstimulated cells the staining
pattern was mainly cytoplasmic. Specificity of the antibody to p65
was further shown by Western blot and by preabsorption with a
specific blocking peptide by IHC. Therefore, the current study
confirms the prior finding of a link between NF-kB/p65 and
prostate cancer outcome and extends the observation by showing
that nuclear localisation of NF-kB/p65 (the biologically active
form) is specifically associated to outcome while cytoplasmic
staining lacked prognostic value.
Other studies also support the concept that nuclear NF-kB
localisation is related to outcome. In another study, nuclear NF-kB
was found in 40% of prostate tumours in 40 specimens assayed
(Lessard et al, 2003). As in the current study, nuclear NF-kB did
not significantly correlate with Gleason score. In a highly selected
series of 30 patients, nuclear localisation was significantly
associated with the prognostic groups (Lessard et al, 2003).
Multivariate analysis was not reported in that study. A study
published recently found nuclear NF-kB expression as an
independent prognostic marker of eventual biochemical recur-
rence in a series of 42 men, all of them with positive surgical
margins after radical prostatectomy. In that study, NF-kB was
measured at the positive surgical margins and 64% of the
specimens were scored as NF-kB positive. In a multivariate
analysis, nuclear NF-kB staining was an independent prognostic
factor in this population (Fradet et al, 2004). In our series reported
here, 54 (62.7%) patients did not have positive surgical margins. Of
note, the percentage of nuclear NF-kB staining was not associated
with the presence or absence of pathologically confirmed surgical
margins. In our multivariate analysis, nuclear NF-kB expression
was confirmed as an independent prognostic marker. Hence, this
result provides novel data by showing that nuclear localisation of
NF-kB has an independent prognostic role in PAC patients that
underwent surgery (also regardless of the pathological state of the
surgical margins). Moreover, a total of five patients had positive
lymph nodes at the time of prostatectomy. NF-kB was not assayed
in these metastatic nodes. However, the five patients had nuclear
NF-kB staining in the corresponding primary prostate cancers,
thus further suggesting a possible link between NF-kB and a
metastatic phenotype.
The above studies and the present data support a role for NF-kB
in the clinical behaviour of prostate cancer. It should be noted,
however, that this field is in an early stage of development and
differences in the IHC methods, scoring interpretations or patient
populations could explain the different rates of expression and
subcellular localisation of NF-kB among studies. In this regard,
however, we should point out that one of us (JSR) reviewed the
scorings of the current and also a previously published series (Ross
et al, 2004), thus reducing the possibility of heterogeneous criteria
for nuclear scoring between these two studies. Collectively, these
two studies concur on a role for NF-kB expression in prostate
Table 3 Multivariate Cox proportional hazards model analysis of
prognostic factors for biochemical relapse in prostate cancer patients
Hazard
ratio
95% confidence
interval P value
Stage 0.91
Organ confined (T2a, T2b) 1.0 Reference
Advanced stage (T3a, T3b) 1.66 0.37–3.00
PSA
a 0.02
o10ngml
 1 1.0 Reference
X10ngml
 1 2.69 1.15–6.30
Gleason
a 0.03
p6 1.0 Reference
X7 2.85 1.10–7.43
Surgical margins
Negative 1.0 Reference 0.66
Positive 0.81 0.31–2.08
Seminal invasion 0.38
Absence 1.0 Reference
Presence 1.66 0.52–5.23
Lymph-node status 0.28
Positive 1.0 Reference
Negative 0.44 0.99–1.99
Cytoplasmic NF-kB 0.86
Negative 1.0 Reference
Positive 0.93 0.40–2.12
Nuclear NF-kB
a 0.002
Absence 1.0 Reference
Presence 5.00 1.84–13.55
aIn a multivariate analysis including PSA, Gleason, stage, cytoplasmic NF-kB and
nuclear NF-kB as continuous variables, P-values were 0.8 for PSA; 0.008 for Gleason;
and 0.003 nuclear NF-kB. See text for additional details.
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scancer clinical behaviour and the current one suggests that the
nuclear (activated) form of p65 is the one that is specifically linked
with a higher likelihood of relapse.
To date, positive margins after prostatectomy, PSA serum levels
prior to prostatectomy, combined Gleason score and tumour node
metastasis (TNM) staging are considered prognostic factors for
prostate cancer progression (Baldwin, 1996; Karin et al, 2004). In
the current series, preoperative PSA levels, Gleason score and
positive margins were significantly associated to the risk of
biochemical relapse by Kaplan–Meier analysis. With the goal of
building on these prognostic factors, we combined nuclear NF-kB
staining results with PSA preoperative levels and Gleason scores,
which were the factors that retained significant prognostic value on
multivariate analysis. Among these three factors, nuclear NF-kB
expression was the more strongly associated to outcome. Promis-
ing results emerged from such analysis since patients with all three
adverse factors (nuclear NF-kB, high PSA and high Gleason)
experienced a biochemical relapse, while all patients with none of
these adverse factors (i.e. undetected nuclear NF-kB, low PSA and
low Gleason) were free of biochemical recurrence. A prior
study with 30 patients that combined nuclear staining with
Gleason grade also improved prediction of clinical outcome
(Lessard et al, 2003). These observations merit further analysis
in prospective studies given its potential interest in adjuvant
management strategies of patients with PAC that undergo
prostatectomy.
Our findings indicate a significant relationship between p65/NF-
kB nuclear staining and biochemical recurrence. However, the
functional relevance of this immunoreactivity on NF-kB activation
is yet unknown. This limitation is based on the fact that p65/NF-kB
nuclear translocation is necessary but not sufficient for NF-kB-
induced transcriptional activity, since both recruitment of NF-kB
to target genes and NF-kB-induced transcriptional events after
recruitment are needed for this to occur (Natoli et al, 2005). It
should be also noted that the minimum percentage of tumour cells
with nuclear p65 staining required to potentially result in
detectable NF-kB-induced transcriptional activity remains unchar-
acterised. Another limitation of using p65/NF-kB as a marker of
activation is that noncanonical pathways, independent of p65,
might also activate NF-kB.
A previous study demonstrated that NF-kB regulates the
transcription of PSA, which is a marker of prostate cancer
progression. Furthermore, the authors also showed that androgen-
independent prostate cancer xenografts had higher constitutive
that NF-kB binding activity than their androgen-dependent
counterparts. These elegant preclinical studies suggested a role
of NF-kB in prostate cancer progression (Chen and Sawyers, 2002)
and our present work extends this view to a clinical setting.
Moreover, in prostate cancer cells, constitutive activation of NF-kB
has been associated to the activation of signalling transduction
pathways involving tyrosine kinases and, more specifically,
molecules such as Rho-A, Ki-Ras or PTEN/Akt (Gasparian et al,
2002; Li and Sarkar, 2002; Kim et al, 2002; Mayo et al, 2002; Hodge
et al, 2003). Transforming growth factor b1 and b2 have been also
involved in NF-kB activation in prostate cancer cells (Park et al,
2003; Lu et al, 2004). These pathways appear to mediate NF-kB
activation as a result of their effect on NF-kB inducing kinase, and
IkB kinase activation (IKK) (Gasparian et al, 2002; Suh et al, 2002).
It is well known that in quiescent cells, NF-kB is bound to IkB
inhibitory proteins and retained in the cytoplasm. However,
phosphorylation of IkBs by IKK results in the rapid degradation of
IkB proteins by the proteasome, freeing p65/NF-kB to enter the
nucleus, bind to DNA, and activate transcription. IkB expression
in prostate cancer has been assessed recently (Ross et al, 2004). In
that study, decreased expression of IkBa in primary prostate
tumours correlated only with tumour grade. However, contrarily
to what might be expected, IkBa expression was not inversely
related to p65/NF-kB. Clearly, there is much work needed to assess
the interplay between the multiple members of the IKK/NF-kB
family. Along this line, an study in endometrial cancer has shown
that nuclear immunostaining for members of the NF-kB family
correlated with negativity for members of the IkB family in some
cases (Pallares et al, 2004). It will be of importance to characterise
whether these molecules, or additional ones that may be shown of
importance in the future, are also linked to NF-kB activation in
human prostate cancers. In addition to its role in prostate cancer
behaviour (Andela et al, 2003), NF-kB activation is also implicated
in chemo- and radioresistance. These observations are comple-
mented by studies showing that NF-kB inhibition is a promising
strategy for prostate cancer treatment, and, particularly, as a
chemo- or radio-sensitisation strategy (Palayoor et al, 1999;
Altuwaijri et al, 2003; Flynn et al, 2003; Kikuchi et al, 2003;
Chendil et al, 2004). Clearly, inhibition of NF-kB may potentiate
the antineoplastic effect of conventional chemotherapeutic agents
(Sanchez-Perez et al, 2002).
In addition to the studies on the expression of NF-kB in human
PACs discussed above, there are data using interleukin(IL)-6 as a
surrogate marker of NF-kB activation in patients with prostate
cancer that further suggest a role of NF-kB in a clinical
setting (Zerbini et al, 2003). Along this line, high serum levels of
IL-6 in PAC patients have been linked to disease progression,
hormone-independence and chemotherapy resistance (Nakashima
et al, 2000; Sanchez-Perez et al, 2002; Michalaki et al, 2004).
Also, dexamethasone, a glucocorticoid used commonly for
prostate cancer treatment, disrupts the NF-kB-IL-6 pathway and
this is thought to mediate the antitumour effect (Nishimura et al,
2001). Finally, recent evidence in a phase I clinical trial has
suggested that the proteasome inhibitor bortezomib has activity
against human prostate cancer and reduces the expression of
serum IL-6 and PSA levels in some patients (Papandreou and
Logothetis, 2004). This is relevant here since the degradation of the
inhibitor of NF-kB, IkB, is dependent on the ubiquitin–protea-
some pathway, and proteasome inhibition results in inhibition of
NF-kB (Elliott and Ross, 2001; Adams, 2004; Papandreou and
Logothetis, 2004).
Based on the preclinical data and the emerging clinical results,
NF-kB appears to be a potential important prognostic factor and/
or target of therapy in human prostate cancer. The current study
shows that NF-kB activation occurs in the transition from a
preneoplastic state to prostate cancer and that NF-kB activation is
a molecular marker that independently predicts a high risk of
biochemical relapse of prostate cancer. These data support the
concept of NF-kB inhibition as an attractive research strategy for
prostate cancer treatment.
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